Abstract

Amyloid precursor protein (APP) modulates glutamate release via cytoplasmic and intravesicular interactions with the synaptic vesicle release machinery. The intravesicular domain, called ISVAID, contains the BACE1 cleavage site of APP. We have tested the functional significance of BACE1 processing of APP using App‐Swedish (App s) knock‐in rats, which carry an App mutation that causes familial Alzheimer's disease (FAD) in humans. We show that in App s rats, β‐cleavage of APP is favored over α‐cleavage. App s rats show facilitated glutamate, but not GABA, release. Our data support the notion that APP tunes glutamate release, and that BACE1 cleavage of the ISVAID segment of APP facilitates this function. We define this phenomenon as BACE1 on APP‐dependent glutamate release (BAD‐Glu). Unsurprisingly, App s rats show no evidence of AD‐related pathology at 15 days and 3 months of age, indicating that alterations in BAD‐Glu are not caused by pathological lesions. The evidence that a pathogenic APP mutation causes an early enhancement of BAD‐Glu suggests that alterations of BACE1 processing of APP in glutamatergic synaptic vesicles could contribute to dementia.

Highlights

  • Amyloid precursor protein (APP) is a ubiquitously expressed type I membrane protein

  • Human genetic data suggest that APP processing plays a significant role in the pathogenesis of both familial and sporadic dementias

  • Humans car‐ rying the Icelandic APP variant, which codes for an APP protein that is inefficiently cleaved by BACE1, are protected from dementia and normal cognitive decline (Jonsson et al, 2012)

Read more

Summary

| INTRODUCTION

Amyloid precursor protein (APP) is a ubiquitously expressed type I membrane protein. In the central nervous system, APP is mainly ex‐ pressed in neurons (Guo et al, 2012). ANOVA summary of PPF at 200 ms ISI: F = 2.353, p = .1088 (not signif‐ icant)] (Figure 4l,m) These data are consistent with the evidence that the ISVAID and JCasp regions of APP form an interactome with glutamatergic but not GABAergic SV and that interfering with the function of ISVAID facilitates glutamate release but does not affect GABA transmission (Yao et al, 2019).

| DISCUSSION
Findings
| EXPERIMENTAL PROCEDURES

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.